Evidence map›Paper›PMID 39588262›Full record

ArticleInternational journal of nanomedicine2024

Artificially Modified NK Cell-Based Synergistic Immuno-Gene-Photodynamic Therapy for Cancer.

Jiale Wu, Kaihong Shi, Wei Chao, Zeyu Qin, Youhui Hu, Yihua Yang, Yuan He, Yabing Hua, Ziming Zhao

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jiale WuDepartment of Pharmacy, Xuzhou Medical University, Xuzhou, People's Republic of China.
Kaihong ShiDepartment of Pharmacy, Xuzhou Medical University, Xuzhou, People's Republic of China.
Wei ChaoDepartment of Pharmacy, Xuzhou Medical University, Xuzhou, People's Republic of China.
Zeyu QinDepartment of Pharmacy, Xuzhou Medical University, Xuzhou, People's Republic of China.
Youhui HuDepartment of Pharmacy, Xuzhou Medical University, Xuzhou, People's Republic of China.
Yihua YangDepartment of Pharmacy, Xuzhou Medical University, Xuzhou, People's Republic of China.
Yuan HeDepartment of Pharmacy, Xuzhou Medical University, Xuzhou, People's Republic of China.
Yabing HuaDepartment of Pharmacy, Xuzhou Medical University, Xuzhou, People's Republic of China.ORCID 0000-0003-2602-2913
Ziming ZhaoDepartment of Pharmacy, Xuzhou Medical University, Xuzhou, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The immunotherapeutic approach utilizing Natural Killer (NK) cells for cancer treatment has garnered significant interest owing to its inherent cytotoxicity, immunomodulatory properties, demonstrated safety in in vivo studies. However, multiple immunosuppressive mechanisms in the tumor microenvironment (TME) suppress the anticancer effect of NK cells in the treatment of solid tumors. Herein, a smart NK cell drug delivery system (DDS) with photo-responsive and TME-responsive properties was designed. Methods: The NK cell DDS consists of two parts: the carrier is living NK cell with pH-low (abbreviated as NK Results: Under near-infrared laser irradiation, SP-NG@NK Discussion: The combined effect of the immunotherapy of NK cell, the gene therapy of siRNA, and the photodynamic therapy of photosensitizer obtained a stronger cancer killing effect in vitro and in vivo. Therefore, this versatile NK cell DDS exhibits a good clinical application prospect.

Indexed as

ImmunotherapyKiller Cells, NaturalPhotochemotherapyPhotosensitizing AgentsReactive Oxygen SpeciesRNA, Small InterferingTumor MicroenvironmentAnimalsCell Line, TumorGenetic TherapyHumansMiceNanogelsNeoplasmsNanogelsPhotosensitizing AgentsReactive Oxygen SpeciesRNA, Small Interferinganticancercellular immunotherapynanogelnatural killer cellsphoto-responsiveTME-responsive

Identifiers

PMID39588262
PMCPMC11587796

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.